Novo Nordisk A/S (NVO) Stock Forecast & Price Target

$38.60 -0.04 (-0.10%)

Closing price 10/12/2026 03:59 PM Eastern

Extended Trading

$38.51 -0.09 (-0.24%)

As of 10/12/2026 07:54 PM Eastern

Compare

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 26 Analyst Ratings

Sell
5

Hold
16

Buy
5

Based on 26 Wall Street analysts who have issued ratings for Novo Nordisk A/S in the last 12 months, the stock has a consensus rating of "Hold." Out of the 26 analysts, 5 have given a sell rating, 16 have given a hold rating, and 5 have given a buy rating for NVO.

Consensus Price Target

$59.44
53.98% Upside

According to the 26 analysts' twelve-month price targets for Novo Nordisk A/S, the average price target is $59.44. The highest price target for NVO is $175.00, while the lowest price target for NVO is $38.00. The average price target represents a forecasted upside of 53.98% from the current price of $38.60.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for NVO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVO Analyst Ratings Over Time

Type	Current Forecast 10/13/25 to 10/13/26	1 Month Ago 9/13/25 to 9/13/26	3 Months Ago 7/15/25 to 7/15/26	1 Year Ago 10/13/24 to 10/13/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	7 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)
Hold	16 Hold rating(s)	16 Hold rating(s)	16 Hold rating(s)	9 Hold rating(s)
Sell	5 Sell rating(s)	3 Sell rating(s)	4 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$59.44	$109.34	$109.84	$142.14
Forecasted Upside	53.98% Upside	154.08% Upside	117.23% Upside	147.18% Upside
Consensus Rating	Hold	Hold	Hold	Hold

NVO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novo Nordisk A/S Stock vs. The Competition

Type	Novo Nordisk A/S	Healthcare Companies	Broader Market
Consensus Rating Score	2.00	2.32	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	53.98% Upside	1,031.70% Upside	19.26% Upside
News Sentiment Rating	Positive News See Recent NVO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/12/2026	BMO Capital Markets 3 of 5 stars	Evan David Seigerman 3 of 5 stars	Set Target	Market Perform	$47.00 ➝ $40.00	+4.38%
10/9/2026	Citigroup 4 of 5 stars		Reiterated Rating	Neutral
10/8/2026	Weiss Ratings 3 of 5 stars		Downgrade	Hold (C-) ➝ Sell (D+)
9/29/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell
9/22/2026	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold ➝ Sell	$38.00	-1.37%
9/21/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Neutral
9/21/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Neutral
9/21/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Neutral
9/21/2026	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kerry Holford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
9/10/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
Your book attached (Ad) Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. Download the Safe Trade Options Formula book for free before access closes
9/7/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Neutral
8/11/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong Sell ➝ Hold
8/6/2026	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Neutral
6/19/2026	Nordea Equity Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy
6/4/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Neutral	$63.00 ➝ $41.00	+6.37%
5/12/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell
3/26/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Peer Perform
3/11/2026	Grupo Santander Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform
3/11/2026	Santander Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform
3/10/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$45.00 ➝ $42.00	+5.60%
3/3/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thibault Boutherin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$42.00 ➝ $40.00	+5.99%
2/24/2026	Kepler Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/5/2026	ABG Sundal Collier Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Sell
2/5/2026	Handelsbanken Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Buy
1/9/2026	CICC Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform	$73.50	+28.19%
12/8/2025	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Eade Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
10/12/2025	SEB Equity Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$625.00 ➝ $530.00	+1,277.77%
9/16/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Neutral ➝ Buy
8/22/2025	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong Sell ➝ Hold
8/13/2025	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Underperform ➝ Neutral
4/17/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Seamus Fernandez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/3/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold
11/6/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight	$160.00 ➝ $160.00	+49.39%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:14 AM ET.

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 8, 2026. Please send any questions or comments about these Novo Nordisk A/S pros and cons to contact@marketbeat.com.

Novo Nordisk A/S
Bull Case

Here are some ways that investors could benefit from investing in Novo Nordisk:

Novo Nordisk is currently trading at $38.19, which is significantly below its 52-week high of $64.16, offering a potential entry point for value-oriented investors who believe the market has overreacted to recent challenges.
The company has a low price-to-earnings ratio of 9.34, indicating that the stock is priced at a discount relative to its earnings power, which may be attractive to fundamental analysts looking for undervalued pharmaceutical assets.
Novo Nordisk is continuing a share-repurchase program that forms part of a planned DKK 15 billion, 12-month buyback, which can provide support for earnings per share and signal management confidence in the valuation.
The company has licensed a Chinese oral-obesity candidate to broaden its pipeline and reduce reliance on injectable GLP-1 products, a strategic move that could expand patient access and diversify revenue streams if development milestones are achieved.
Novo Nordisk recently reported strong financial performance with a return on equity of 58.61% and a net margin of 35.36% for the quarter ended June 30, 2026, demonstrating robust profitability despite market headwinds.

Novo Nordisk A/S
Bear Case

Investors should be bearish about investing in Novo Nordisk for these reasons:

Competition in obesity treatments is intensifying, with reports indicating that Novo Nordisk is losing market share as investors question whether its pipeline beyond GLP-1 therapies is broad enough to sustain growth against rivals like Eli Lilly.
The FDA extended its review of denecimig, Novo Nordisk’s hemophilia A treatment, due to remediation work at a manufacturing facility, which postpones a potential product launch and highlights ongoing manufacturing risks.
Wall Street analysts have a consensus rating of "Hold" with a target price of $64.94, suggesting limited near-term upside potential, while several firms, including Wall Street Zen and CFRA, have recently downgraded or turned bearish on the stock.
Novo Nordisk recently cut its dividend from $1.2751 to $0.5786, a significant reduction that may disappoint income-focused investors who rely on the company's payout for yield.
Institutional investors have shown mixed sentiment, with Eastern Bank decreasing its stake by 32.8% in the third quarter, while short interest remains elevated at over 26 million shares, indicating persistent bearish positioning in the market.

NVO Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $59.44, with a high forecast of $175.00 and a low forecast of $38.00.

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 5 sell ratings, 16 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.

According to analysts, Novo Nordisk A/S's stock has a predicted upside of 53.98% based on their 12-month stock forecasts.

Over the previous 90 days, Novo Nordisk A/S's stock had 4 downgrades and 2 upgrades by analysts.

Novo Nordisk A/S has been rated by research analysts at Barclays, Berenberg Bank, BMO Capital Markets, Cfra, Citigroup, Deutsche Bank Aktiengesellschaft, DZ Bank, HSBC, Jefferies Financial Group, JPMorgan Chase & Co., UBS Group, Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like Novo Nordisk A/S less than other "healthcare" companies. The consensus rating score for Novo Nordisk A/S is 2.00 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how NVO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Novo Nordisk A/S Recommendations

MarketBeat monitors more than a dozen sources for Novo Nordisk A/S analyst ratings, with the most recent rating issued on 10/12/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Stock Forecast & Price Target

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

NVO Analyst Ratings Over Time

NVO Analyst Recommendations By Month

NVO Price Targets by Month

Novo Nordisk A/S Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

Novo Nordisk A/S
Bull Case

Novo Nordisk A/S
Bear Case

NVO Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Novo Nordisk A/S Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novo Nordisk A/S (NVO) Stock Forecast & Price Target

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

NVO Analyst Ratings Over Time

NVO Analyst Recommendations By Month

NVO Price Targets by Month

Novo Nordisk A/S Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

Novo Nordisk A/S Bull Case

Novo Nordisk A/S Bear Case

NVO Forecast - Frequently Asked Questions

What is Novo Nordisk A/S's forecast for 2026?

Should I buy or sell Novo Nordisk A/S stock right now?

Does Novo Nordisk A/S's stock price have much upside?

Has Novo Nordisk A/S been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Novo Nordisk A/S?

Do Wall Street analysts like Novo Nordisk A/S more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Novo Nordisk A/S Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Novo Nordisk A/S
Bull Case

Novo Nordisk A/S
Bear Case